Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
3 articles
Newest firstThe small (N = 102) prospective study by Bar-Sela and colleagues at Emek Medical Center in Israel) regarding diminished efficacy of immunotherapy in the setting of cannabis use would be an important discovery which could theoretically benefit the outcomes of oncology patients if verified by independent research teams, including by basic scientists. However, if this finding was spurious, clinical practice guideline…
Open article record in new tab ↗A retrospective (N = 140) and a prospective (N = 102) observational Israeli study by Bar-Sela and colleagues about cannabis potentially adversely impacting the response to immunotherapy have together been cited 202 times, including by clinical practice guidelines. There have also been concerns on PubPeer outlining irregularities and unverifiable information in their statistics and numerous errors in calculating pe…
Open article record in new tab ↗BackgroundNivolumab in combination with chemotherapy significantly improves survival in patients with gastric/gastroesophageal junction (G/GEJ)/esophageal adenocarcinoma.The purpose of this study was to evaluate the cost-effectiveness of Nivolumab plus chemotherapy for G/GEJ/esophageal adenocarcinoma. MethodsA Markov model was developed on the basis of the US healthcare payers perspectives. We estimated the costs…
Open article record in new tab ↗